[ad_1]
Zydus Lifesciences on Tuesday mentioned it has acquired approval from the US well being regulator to market a generic medicine to stop and deal with blood clots. The corporate has acquired approval from the US Meals and Drug Administration (USFDA) to market Apixaban tablets in strengths of two.5 and 5 mg, in response to a regulatory submitting.
Apixaban blocks the exercise of sure clotting substances within the blood. It’s used to decrease the danger of stroke or a blood clot in individuals with a coronary heart rhythm dysfunction referred to as atrial fibrillation.
It is usually used to cut back the danger of forming a blood clot within the legs and lungs of people that have simply had hip or knee alternative surgical procedure.
The drug might be manufactured on the Zydus group’s formulation manufacturing facility at Moraiya, Ahmedabad.
As per IQVIA MAT December 2022 knowledge, Apixaban tablets had annual gross sales of USD 18,876 million within the US.
[ad_2]
Source link
